Research Analysts Set Expectations for Geron FY2027 Earnings

Geron Co. (NASDAQ:GERN - Free Report) - B. Riley reduced their FY2027 earnings per share estimates for Geron in a note issued to investors on Tuesday, February 18th. B. Riley analyst K. Patel now anticipates that the biopharmaceutical company will post earnings per share of $0.28 for the year, down from their prior estimate of $0.36. B. Riley currently has a "Buy" rating and a $3.50 target price on the stock. The consensus estimate for Geron's current full-year earnings is ($0.25) per share.

A number of other research firms have also weighed in on GERN. Needham & Company LLC increased their target price on shares of Geron from $6.00 to $7.00 and gave the stock a "buy" rating in a report on Monday, January 13th. Barclays upgraded shares of Geron to a "strong-buy" rating in a report on Friday, November 29th. Finally, HC Wainwright reiterated a "buy" rating and set a $9.00 target price on shares of Geron in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Geron presently has a consensus rating of "Moderate Buy" and an average price target of $6.91.

Geron Trading Down 2.1 %

Shares of Geron stock traded down $0.06 during trading on Wednesday, reaching $2.58. 8,935,592 shares of the stock were exchanged, compared to its average volume of 11,720,026. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. The stock's fifty day moving average is $3.13 and its 200 day moving average is $3.88. The firm has a market cap of $1.56 billion, a price-to-earnings ratio of -8.05 and a beta of 0.53. Geron has a 1 year low of $1.64 and a 1 year high of $5.34.

Hedge Funds Weigh In On Geron

Institutional investors and hedge funds have recently made changes to their positions in the business. RTW Investments LP bought a new position in shares of Geron during the third quarter valued at approximately $200,268,000. Nvest Financial LLC bought a new position in shares of Geron during the fourth quarter valued at approximately $693,000. Janus Henderson Group PLC increased its position in shares of Geron by 140.0% during the third quarter. Janus Henderson Group PLC now owns 22,565,846 shares of the biopharmaceutical company's stock valued at $102,193,000 after acquiring an additional 13,163,889 shares in the last quarter. Barclays PLC increased its position in shares of Geron by 114.9% during the third quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company's stock valued at $5,902,000 after acquiring an additional 694,931 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Geron during the third quarter valued at approximately $1,102,000. Institutional investors own 73.71% of the company's stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.